FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232184817> ?p ?o ?g. }

• W4232184817 abstract "Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions. One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-specified systemic therapy (Group 1: immunotherapy/targeted; Group 2: cytotoxic; Group 3: observation). SABR is to be completed within 2 weeks, allowing for rapid initiation of systemic therapy. Recommended SABR doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, chosen to minimize risks of toxicity. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, time to development of new metastatic lesions, quality of life, and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. This study will provide an assessment of the impact of SABR on clinical outcomes and quality of life, to determine if long-term survival can be achieved for selected patients with 4–10 oligometastatic lesions. Clinicaltrials.gov identifier: NCT03721341 . Date of registration: October 26, 2018." @default.
• W4232184817 created "2022-05-12" @default.
• W4232184817 creator A5007941548 @default.
• W4232184817 creator A5008861959 @default.
• W4232184817 creator A5016085567 @default.
• W4232184817 creator A5017209583 @default.
• W4232184817 creator A5018769500 @default.
• W4232184817 creator A5019768466 @default.
• W4232184817 creator A5030840846 @default.
• W4232184817 creator A5031508148 @default.
• W4232184817 creator A5032441898 @default.
• W4232184817 creator A5033401275 @default.
• W4232184817 creator A5033944759 @default.
• W4232184817 creator A5038486476 @default.
• W4232184817 creator A5039156745 @default.
• W4232184817 creator A5039412904 @default.
• W4232184817 creator A5040003025 @default.
• W4232184817 creator A5049510778 @default.
• W4232184817 creator A5050537425 @default.
• W4232184817 creator A5055466353 @default.
• W4232184817 creator A5056712435 @default.
• W4232184817 creator A5057971434 @default.
• W4232184817 creator A5068938553 @default.
• W4232184817 creator A5070984695 @default.
• W4232184817 creator A5077453712 @default.
• W4232184817 creator A5088939728 @default.
• W4232184817 creator A5089705721 @default.
• W4232184817 date "2019-08-19" @default.
• W4232184817 modified "2023-10-11" @default.
• W4232184817 title "Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial" @default.
• W4232184817 cites W1499990855 @default.
• W4232184817 cites W2030505692 @default.
• W4232184817 cites W2033052459 @default.
• W4232184817 cites W2090749716 @default.
• W4232184817 cites W2127835502 @default.
• W4232184817 cites W2131110909 @default.
• W4232184817 cites W2133422369 @default.
• W4232184817 cites W2142138307 @default.
• W4232184817 cites W2143193944 @default.
• W4232184817 cites W2170281599 @default.
• W4232184817 cites W2186638557 @default.
• W4232184817 cites W2294395959 @default.
• W4232184817 cites W2434730538 @default.
• W4232184817 cites W2498309700 @default.
• W4232184817 cites W2536769127 @default.
• W4232184817 cites W2571554990 @default.
• W4232184817 cites W2586407709 @default.
• W4232184817 cites W2596956169 @default.
• W4232184817 cites W2597498208 @default.
• W4232184817 cites W2606603908 @default.
• W4232184817 cites W2608738563 @default.
• W4232184817 cites W2609243345 @default.
• W4232184817 cites W2744155804 @default.
• W4232184817 cites W2748446253 @default.
• W4232184817 cites W2761351587 @default.
• W4232184817 cites W2788208686 @default.
• W4232184817 cites W2790122515 @default.
• W4232184817 cites W2796600021 @default.
• W4232184817 cites W2797282777 @default.
• W4232184817 cites W2805412777 @default.
• W4232184817 cites W2806023863 @default.
• W4232184817 cites W2807832468 @default.
• W4232184817 cites W2810387901 @default.
• W4232184817 cites W2897004478 @default.
• W4232184817 cites W2939770857 @default.
• W4232184817 cites W4240340450 @default.
• W4232184817 doi "https://doi.org/10.1186/s12885-019-5977-6" @default.
• W4232184817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31426760" @default.
• W4232184817 hasPublicationYear "2019" @default.
• W4232184817 type Work @default.
• W4232184817 citedByCount "141" @default.
• W4232184817 countsByYear W42321848172019 @default.
• W4232184817 countsByYear W42321848172020 @default.
• W4232184817 countsByYear W42321848172021 @default.
• W4232184817 countsByYear W42321848172022 @default.
• W4232184817 countsByYear W42321848172023 @default.
• W4232184817 crossrefType "journal-article" @default.
• W4232184817 hasAuthorship W4232184817A5007941548 @default.
• W4232184817 hasAuthorship W4232184817A5008861959 @default.
• W4232184817 hasAuthorship W4232184817A5016085567 @default.
• W4232184817 hasAuthorship W4232184817A5017209583 @default.
• W4232184817 hasAuthorship W4232184817A5018769500 @default.
• W4232184817 hasAuthorship W4232184817A5019768466 @default.
• W4232184817 hasAuthorship W4232184817A5030840846 @default.
• W4232184817 hasAuthorship W4232184817A5031508148 @default.
• W4232184817 hasAuthorship W4232184817A5032441898 @default.
• W4232184817 hasAuthorship W4232184817A5033401275 @default.
• W4232184817 hasAuthorship W4232184817A5033944759 @default.
• W4232184817 hasAuthorship W4232184817A5038486476 @default.
• W4232184817 hasAuthorship W4232184817A5039156745 @default.
• W4232184817 hasAuthorship W4232184817A5039412904 @default.
• W4232184817 hasAuthorship W4232184817A5040003025 @default.
• W4232184817 hasAuthorship W4232184817A5049510778 @default.
• W4232184817 hasAuthorship W4232184817A5050537425 @default.
• W4232184817 hasAuthorship W4232184817A5055466353 @default.
• W4232184817 hasAuthorship W4232184817A5056712435 @default.
• W4232184817 hasAuthorship W4232184817A5057971434 @default.
• W4232184817 hasAuthorship W4232184817A5068938553 @default.
• W4232184817 hasAuthorship W4232184817A5070984695 @default.
• W4232184817 hasAuthorship W4232184817A5077453712 @default.

• next